87
Participants
Start Date
September 30, 2001
Primary Completion Date
September 30, 2006
Study Completion Date
September 30, 2006
bexarotene
This drug is a retinoid. The anti-tumor action of retinoids, as well as their potential in chemoprevention, supports the need to further identify the spectrum of responsive tumors, to identify the molecular mechanisms associated with retinoid action, and to identify and develop new retinoids that have unique properties and an improved therapeutic index.
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington D.C.
Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston
Cancer Therapy and Research Center, San Antonio
M.D. Anderson Cancer Center at University of Texas, Houston
National Cancer Institute (NCI)
NIH
Baylor Breast Care Center
OTHER